Abstract: The invention relates to vitamin D derivatives and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having different interesting biological properties, including vitamin D nuclear receptor (VDR) agonist activity, as well as therapeutics methods by administering said compounds, in particular for treating cancer, psoriasis, autoimmune diseases, osteodistrophy and osteoporosis. It further relates to pharmaceutical compositions comprising said compounds and methods for preparing the same.

Abstract: The invention relates to vitamin D derivatives and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having different interesting biological properties, including vitamin D nuclear receptor (VDR) agonist activity, as well as therapeutics methods by administering said compounds, in particular for treating cancer, psoriasis, autoimmune diseases, osteodistrophy and osteoporosis. It further relates to pharmaceutical compositions comprising said compounds and methods for preparing the same.

Abstract: The present invention relates to the identification of novel biologically active compounds having an agonist or an antagonist effect on the transcriptional-activating activity of the Estrogen-Related Receptor 3 (ERR3).

Abstract: Polypeptides derived from vitamin D nuclear receptor, which nuclear receptor comprises a ligand-binding domain, or LBD, which contains a flexible insertion domain. The polypeptides are charactarised in that the LBD flexible insertion domain is modified by substituting or suppressing at least 30 acids. The invention also concerns the use of the polypeptides in particular for screening synthetic vitamin D analogues or for producing tests (double or triple hybrid) for identifying other proteins (activator, repressor, . . . ) interacting with the vitamin D receptor using constructs containing the polypeptide used with Gal4 for example, or for analyzing three dimensional structures of complexes formed between the polypeptides and a particular molecule by crystallography or NMR.

Abstract: The present invention relates to the identification of novel biologically active compounds having an agonist or an antagonist effect on the transcriptional-activating activity of the Estrogen-Related Receptor 3 (ERR3).

Abstract: The invention relates to polypeptides derived from the retinoic acid-related orphan receptor (ROR) in mammals, characterized in that they are delimited in their N-terminal extremity by an amino-acid located between positions 1 to 209, and in their C-terminal extremity by an amino-acid located between positions 450 to 452 of the rat ROR&bgr;, &agr;, or &ggr;, or by an amino-acid located at corresponding positions in nuclear receptor ROR of other subtypes than &agr;, &bgr; and &ggr;, and/or of the other mammals. The invention also relates to the use of these polypeptides, or of the molecular complexes or the crystals containing them, for carrying out:—a process for the screening of a ROR-LBD ligand which is an agonist, or an antagonist of said receptor,—or a process for the analysis of the tridimensional structure of the complexes formed with said polypeptides, molecular complexes or crystals and a particular compound.

Abstract: The present invention relates to the identification of novel biologically active compounds having an agonist or an antagonist effect on the transcriptional-activating activity of the Estrogen-Related Receptor 3 (ERR3).

Abstract: The invention relates to the spatial structure of the ligand-binding domain of the ultraspiracle protein, to the use of this structure for generating protein models of this protein in various conformations and of related proteins, and to methods of finding ligands of the ultraspriracle protein and of related proteins.